Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial
Open Access
- 18 June 2025
- journal article
- Published by Elsevier in JHEP Reports
- Vol. 7 (11) , 101483
Abstract
No abstract availableKeywords
Funding Information
- Altimmune Inc
This publication has 33 references indexed in Scilit:
- A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseJournal of Hepatology, 2023
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialJournal of Hepatology, 2022
- Design and characterization of a surfactant‐conjugated, long‐acting, balanced GLP‐1/glucagon receptor dual agonistPeptide Science, 2021
- Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASHHepatology, 2020
- Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-AnalysisClinical Gastroenterology and Hepatology, 2020
- The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASHHepatology, 2019
- How bariatric surgery affects liver volume and fat density in NAFLD patientsSurgical Endoscopy, 2017
- Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgeryMetabolism, 2009
- Relative quantitative analysis of glucagon receptor mRNA in rat tissuesMolecular and Cellular Endocrinology, 1994
- The role of glucagon in the regulation of plasma lipidsMetabolism, 1979